Application of preclinical data to initiate the modified continual reassessment method for maximum tolerated dose-finding trials

Authors
Citation
I. Mahmood, Application of preclinical data to initiate the modified continual reassessment method for maximum tolerated dose-finding trials, J CLIN PHAR, 41(1), 2001, pp. 19-24
Citations number
12
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
JOURNAL OF CLINICAL PHARMACOLOGY
ISSN journal
00912700 → ACNP
Volume
41
Issue
1
Year of publication
2001
Pages
19 - 24
Database
ISI
SICI code
0091-2700(200101)41:1<19:AOPDTI>2.0.ZU;2-C
Abstract
This study was conducted to evaluate whether the allometric approach can be used to predict maximum tolerated dose (MTD) in humans from animal data. T wenty-five anticancer drugs were taken from the literature and used in this analysis. The results of the study indicate that MTD can be predicted with reasonable accuracy using interspecies scaling. The predicted MTD can then be applied to the modified continual reassessment method retrospectively f or the selection of initial and subsequent doses of anticancer drugs in the patient population. This approach can save time and avoid many unnecessary steps to attain MTD in humans if it could be applied prospectively. Journa l of Clinical Pharmacology, 2001;41:19-24 (C) 2001 the American College of Clinical Pharmacology.